TROP-2 Inhibitors Are Explored in Breast Cancer
Jun 28, 2025 · Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.
From Guidelines to Practice: Clinical Perspectives on Mitomycin …
4 days ago · Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and mitomycin with radiation, which remains the …
Current Treatment Landscape for Treatment-Naive CLL
Jun 30, 2025 · Panelist discusses how frontline CLL treatment has evolved from choosing between continuous oral therapy vs fixed-duration combination therapy to now including new …
Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer
Jun 30, 2025 · New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.
Treatment Selection Considerations in mCRPC
Jun 30, 2025 · Treatment of metastatic castration-resistant prostate cancer (mCRPC) mCRPC depends heavily on prior therapies, disease characteristics, and genetic profiles. For patients …
FDA Approves Updated Labels on CAR T-Cell Therapies, …
Jun 27, 2025 · FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.
Considering How TAILORx Transformed Node-Negative Breast …
5 days ago · During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.
Targeted CLL Agents Reshape Treatment Paradigm, But Unmet …
Jun 26, 2025 · Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line or later CLL treatment.
Perspectives on the Future of mCRPC
Jun 30, 2025 · An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand …
Elraglusib Shows Promising OS in Metastatic Pancreatic Cancer …
Jun 30, 2025 · Elraglusib shows promise in enhancing survival rates for metastatic pancreatic cancer, particularly in high-risk patients with liver metastases.